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Abstract 
Childhood cancers are a broad range of diseases. Research on the chemopreventive potential of non-steroidal anti-inflammatory drugs, 
such as aspirin (acetylsalicylate) has yet to be fully directed towards childhood cancers. A prima facie hypothesis on salicylate and 
childhood cancer would therefore be based on several factors. Firstly, salicylate inhibits the production of inflammatory prostaglandins, 
which have been shown to stimulate the growth of cancer cells. Secondly, salicylate inhibits the growth of cancer cells in pre-clinical 
models. Thirdly, salicylate is a natural component of fruits and vegetables so it is consumed within the diet. Further research, of which 
some possibilities are identified, is recommended. 
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Introduction 
Aspirin, acetylsalicylate, belongs to a class of medicines known 
as non-steroidal anti-inflammatory drugs (NSAIDs). These 
medicines are widely used for the treatment and alleviation of 
pain, inflammation and fever. However, undesirable effects, 
such as gastrointestinal irritation and an increased risk of 
cardiovascular events, limit the use of these medicines [1]. 
In low doses of 75–150 mg/d, aspirin is used to reduce the risk 
of cardiovascular disease [2]. There is also a growing evidence-
base that aspirin and other NSAIDs might reduce the risk of 
developing a wide range of cancers [3]. Hypotheses 
underpinning this possible benefit are that NSAIDs might exert 
chemopreventive effects during the process of cancer 
development, so-called multistage carcinogenesis [4]. One 
contributory effect is believed to be due, at least part, to the 
inhibition of cyclo-oxygenase (COX) enzymes, leading to the 
reduced production of pro-inflammatory eicosanoids, like 
prostaglandins [4]. COX-1 is expressed constitutively whilst 
COX-2 is induced during carcinogenesis, leading to high levels 
of prostaglandin E2 production that supports cancer growth. In 
addition, aspirin and other NSAID have also been shown to 
directly inhibit the growth of cancer cells through COX-2-
independent mechanisms and by inhibition of angiogenesis [4]. 
Furthermore, salicylate, which is the principle active metabolite 
of aspirin in humans, has been shown to induce programmed 
cell death, apoptosis, in several cancer cell lines [4]. 
Childhood cancers are a broad range of diseases that are rare 
everywhere in the world [5]. In so-called developed countries, 
however, childhood cancers are the commonest cause of 
disease-related deaths in childhood, carrying with them great 
emotional and economic cost [6]. The descriptive epidemiology 
of childhood cancer also varies in accuracy. In countries where 
registration of childhood cancer cases is almost complete, the 
epidemiology of childhood cancer shows little or no increase in 
incidence of new cases per annum [7]. By contrast, in some 
countries, for example some Eastern European countries [8] 
and India [9], registration is poor and compromises research on 
trend analysis and disease aetiology. In low-income countries, it 
has been suggested that hospital-based registries could be 
developed [10]. 
Although there is considerable interest and active research on 
the chemopreventive potential of NSAIDs, this has yet to be 
directed towards childhood cancers to the same extent as adult 
malignancies. In this paper, hypotheses are presented for the 
first time in the expanded form that salicylate might exert 
benefits against childhood cancer. These hypotheses build on 
previous work [11] and possible future lines of research are 
identified. To offer a broader context, some aspects of 
childhood cancer aetiology are initially considered. Outside of 
the scope of this paper, however, is the proposal and broader 
debate that salicylate might be reclassified as vitamin S [12]. 
 
Aetiological aspects of childhood cancer  
With the exception of retinoblastoma (RB), where more than 
40% of cases are due to an inherited mutation in the RB tumour 
suppressor gene [13], as well as in limited cases of Wilms 
tumour, Hodgkin's lymphoma and neuroblastoma, there is no 
clear evidence for a familial predisposition to childhood cancers 
[14–16]. This would in turn suggest a prominent role of 
modifiable risk factors in the aetiology of childhood cancer. 
One such risk factor might be the exposure to infections. There 
is a hypothesis for an infectious aetiology for acute 
lymphoblastic leukaemia (ALL) but not for acute non-
lymphoblastic leukaemia (AnLL) or for solid tumours such as 
those of the central nervous system (CNS) and neuroblastoma 
[17]. More generally, it is known that certain infections can 
predispose to cancer [18], such as human papillomavirus and 
the hepatitis virus. Vaccination programmes against these 
viruses are helpful to reduce the risk of cervical and liver 
cancer, respectively. Perhaps aspirin may also influence the risk 
of viral-induced cancers such as those caused by the Epstein-
Barr virus [19] and Cytomegalovirus [20] by inhibiting cell 
invasion and exerting anti-viral effects, respectively. 
Whilst recognizing the complexity of childhood cancer as a 
group of diseases, coupled to the difficulties of differentiating 
association from causation, two further modifiable risk factors 
are briefly discussed. 
Maternal exposure to risk factors 
Based on a study in the United Kingdom, socio-economic status 
does not appear to be a determinant of ALL in children [21]. 
This is potentially important since socio-economic status may 
be predictive of maternal lifestyle. Although much has been 
documented with regard to maternal diet, smoking, alcohol 
consumption and recreational or prescription drug use during 
pregnancy, there is no consistent evidence to support a link with 
any of these factors and childhood leukaemia [22]. 
Maternal exposure to solvents could further be investigated for 
ALL but evidence to date is limited given that it is based on self-
reported data [23]. As a more general point, the adverse health 









effects linked to maternal exposures include foetal death, birth 
defects, being small for gestational age, pre-term birth, clinically 
overt cognitive, neurologic and behavioural abnormalities, 
subtle neuropsychological deficits, childhood cancer, asthma, 
other respiratory diseases and acute poisoning [24]. 
So, there is a broader challenge of correlating exposure to 
outcome for child health [25]. Expert groups faced with 
evaluating epidemiological evidence of potential causal 
relationships repeatedly encounter problems in summarizing the 
available data. 
 
Vitamin influence on childhood cancer risk 
Folic acid, vitamin B, is used in several countries as part of 
commercially available supplements and fortified foods for 
disease prevention [26]. Supplementations of folic acid to 
pregnant women have a beneficial effect in reducing the risk for 
neural tube defects in the offspring. There is evidence 
suggesting that folic acid supplementation also may reduce the 
risk of certain childhood cancers. Folic acid fortification in a 
Canadian study was associated with a significant 60% reduced 
risk for neuroblastoma development, whereas the incidence of 
ALL and hepatoblastoma remained unchanged [27]. 
Another study reported that maternal use of folic acid, both pre-
conception and peri-conception, reduced the risk of brain 
tumours in the offspring. This may suggest that perhaps folic 
acid supplementation might prevent the development of cancers 
in a site-specific manner [28]. Moreover, pre-conception use of 
maternal multivitamin supplements containing folic acid 
demonstrated protective effects for childhood leukaemia, 
paediatric brain tumours and neuroblastoma [29]. Partly in 
contrast, a study from Germany showed that maternal use of 
multivitamins, folate and iron supplements reduced the risk of 
non-Hodgkin’s lymphoma and perhaps leukaemia, but not 
tumours of the CNS. This study also demonstrated an 
associated increased risk for neuroblastoma in the offspring 
[30]. 
It has further been suggested that vitamin D has potential anti-
cancer activity and vitamin D status is sub-optimal in many 
children in North America [31]. There is also a hypothesis of an 
increased risk of ALL following vitamin K given to newborns 
[32]. These influences, although questions remain, highlight the 
possible role of dietary components in the aetiology of childhood 
cancer.  
 
Hypotheses that salicylate might protect 
against childhood cancer 
The evidence on the factors of childhood cancer is far from 
complete and there are risk-significant unresolved questions 
and gaps in knowledge. Given this, there is capacity for 
additional factors that influence childhood cancer risk to be put 
forward. It is on this basis that there is scope to suggest 
hypotheses that salicylate might help reduce the risk of 
childhood cancer. 
Aspirin is now rarely used in children because of an association 
with a condition known as Reye’s syndrome [33]. It has been 
suggested that the reduced use of the medicine in children 
could be a factor in increasing childhood asthma [34]. 
The rare use of aspirin in children, which per se may have 
negative consequences, focuses a prima facie hypothesis on 
salicylate and childhood cancer on two factors. Firstly, salicylate 
exerts apoptotic effects on a broad range of cancer cell lines 
and NSAIDs inhibit the development and progression on pre-
clinical in vivo models of neuroblastoma and medulloblastoma 
[35–37]. 
Secondly, salicylate is a natural component of fruits and 
vegetables so it is consumed in the diet [38]. Salicylate plays an 
important role in protecting tissues from disease and damage 
through the induction of apoptosis and in the inflammatory 
resolution phase. It therefore follows that those fruits and 
vegetables grown in natural conditions where they are exposed 
to the environment and pathogenic challenge express the 
highest levels of salicylate in their tissues [38]. A related 
hypothesis is that humans are becoming increasingly salicylate 
deficient [39] due to changes in food production and 
consumption patterns [40]. 
There has been interest in the vegetarian diet and reduced 
cancer risk [41]. It would therefore appear that the 
pharmacological properties of salicylate from pharmaceutical or 
dietary sources have relevance to human health and disease. 
Evidence extending over several decades demonstrates that 
salicylate exerts a number of effects on prostaglandin pathways 
[42]. More recent evidence suggests that these effects appear 
to be dependent, at least in part, on the intra-cellular oxidative 
conditions [43]. Salicylate might also exert anti-inflammatory 
effects through non-COX mechanisms [44]. For example, there 
is evidence that salicylate exerts its anti-inflammatory action in 
part through inhibition of the extracellular signal-regulated 
kinase (ERK) pathway. This is potentially important given that 
tumour necrosis factor-  can induce the ERK pathway [45]. 









There is also evidence that certain metabolites of salicylate may 
inhibit COX-2-dependent prostaglandin E2 formation at sites of 
inflammation [46]. Further research would appear to be 
warranted to clarify the anti-inflammatory pathways of salicylate 
and metabolites [47]. Recently, acetylation of COX-2 by low-
dose aspirin was shown to redirect the catalytic activity of COX-
2 away from generating pro-inflammatory prostaglandins and 
thromboxanes towards the production of lipoxins. The COX-2 
enzyme with this modification remains catalytically active [48]. 
In contrast to prostaglandin E2, which has proven pro-
carcinogenic effects, one of the major end products of 
acetylated COX-2 is lipoxins (15-epi-lipoxin A4), which have 
anti-tumourigenic effects [49]. In addition, other lipid mediators 
such as resolvins and protectins, important in the resolution 
phase of inflammation, are also produced by COX-2 and 
lipoxygenase enzymes from the omega-3 fatty acids 
eicosapentanoic acid (EPA) and docohexanenoic acid (DHA), 
which could explain some of the anti-carcinogenic properties of 
these compounds [48,49]. It is possible that the ingestion of 
salicylate exerts multiple effects, directly as a parent compound 
and also with respect to the metabolites produced. Research on 
these effects in human health and disease might help to identify 
new therapeutic targets for cancer control, both in children and 
adults. 
 
Effects of NSAIDs on pre-clinical models of solid 
childhood tumours
Several studies have shown that different NSAIDs inhibit the 
growth of some solid childhood cancer cells in vitro, notably 
neuroblastoma, medulloblastoma including primitive 
neuroectodermal tumours (PNET) osteosarcoma and 
rhabdomyosarcoma [35–37,50–58]. Furthermore, both the 
COX-2-specific NSAID celecoxib and the dual COX-1/COX-2 
inhibitor diclofenac significantly inhibit neuroblastoma and 
medulloblastoma growth in animal models [35–37]. 
Moreover, prophylactic treatments with celecoxib inhibit or 
prevent the development of neuroblastoma xenografts in 
rodents [54]. Celecoxib also significantly enhanced the effects 
of common chemotherapeutic drugs used in the treatment of 
neuroblastoma and medulloblastoma [35–37]. Medulloblastoma, 
PNET and neuroblastoma primary tumours express high levels 
of COX-2 and microsomal prostaglandin E synthase-1 
(mPGES-1), the two enzymes responsible for converting 
arachidonic acid, a dietary fatty acid and precursor to 
eicosanoid synthesis, to prostaglandin E2. Compared to non-
malignant nervous tissue, neuroblastoma, medulloblastoma and 
other childhood nervous tumours contain increased levels of 
arachidonic acid [60,61]. 
The presence of high levels of COX-2 and mPGES-1 in these 
tumours may therefore generate a pathogenic environment for 
the increased production of pro-carcinogenic prostaglandins. It 
has also been shown that prostaglandin E2 increases 
proliferation of medulloblastoma cells and patients with 
malignant brain tumours have significantly higher 
concentrations of prostaglandin E2 in their tumours and plasma 
compared to patients with benign brain tumours or non-cancer 
control patients [59–61]. Moreover, the concentration of 
prostaglandin E2 in plasma decreases following neurosurgical 
resection of both malignant and benign brain tumours [61]. 
Taken together, these results suggest that dietary salicylate 
might be beneficial in the prevention of at least a subset of 
childhood cancers.  
Salicylate prevention of first and subsequent 
childhood cancers?
Whilst recognizing that there may be some risks with ingesting 
high-levels salicylate during pregnancy [62], women may be 
exposed in two broad ways, which confer benefit. As suggested 
previously, the first of these is through dietary sources. The 
second is that some women might take aspirin, and there is 
evidence that in some cases of pre-eclampsia, low-doses of the 
medicine might be beneficial and increase birth weight [63]. This 
is potentially important per se given that low birthweight has 
been associated with numerous health problems during life [64]. 
One possible line of future research is therefore to understand 
the levels and effects of maternal exposure to salicylate on the 
risk of childhood cancer. More generally, such research could 
also examine maternal exposure to salicylate and other aspects 
of childhood health. 
Maternal salicylate would also be expected to be secreted 
through breast milk. The effect of breastfeeding on childhood 
cancer risk is uncertain and increasing breastfeeding from 50% 
to 100% in the population has been estimated to prevent 
perhaps 5% of cases of childhood acute leukaemia or 
lymphoma at most [65]. Another consideration is the evidence 
that childhood fruit consumption may have a long-term 
protective effect on cancer risk in adults. Further prospective 
studies, with individual measures of diet, are required to further 
elucidate these relations [66]. 
There is evidence of a sustained increased risk of second 
malignancy in those treated for primary cancer, especially those 









diagnosed in childhood [67]. A study of salicylate levels in 
childhood cancer patients might therefore be a valuable 
research avenue. Such studies might measure salicylate levels 
non-invasively using readily available bodily fluids, such as 
urine. Perhaps dietary salicylate, particularly high in fruits and 
vegetables grown under organic conditions, could help reduce 
the risk of second malignancy. This could be tested 
experimentally through randomized trials with the active 
intervention being exposure to salicylate through fruits and 
vegetables. 
Furthermore, salicylate might be an endogenous protective 
agent against cancer. There is evidence that humans have the 
ability to synthesize salicylate [68]. Salicylate deficiency or 
impaired metabolic pathways leading to synthesis might 
therefore be a factor in childhood cancer risk. In rare cases, 
however, some individuals experience salicylate intolerance 
[69]. A study of cancer risk in intolerant individuals might also be 
a productive research line. If salicylate does confer protection 
then intolerant individuals might have an increased risk of 
cancer. 
Furthermore, laboratory-based experiments would also be 
helpful to increase knowledge and understanding of the effects 
of salicylate on childhood cancer. 
 
Some contemporary issues in childhood 
cancer 
Research evidence suggests that the continuing needs of 
childhood-cancer survivors include the provision of information 
of the later effects of treatment and self-care [70]. With respect 
to self-care, this might include tailored exercise programmes 
given that reduced physical activity is often a feature of 
childhood cancer, during and after treatment [71].  
Across the world, childhood-cancer survival rates are 
increasing, for example one study from Singapore suggests that 
approximately 60% of patients overall survive more than two 
years [72]. Social aspects of surviving childhood cancers, such 
as impact on relationships, possibly highlight the need for longer 
support services to be offered [73]. Such psychosocial support 
might also be delivered to family members of childhood-cancer 
survivors [74]. 
Efforts to improve the cosmetic aspects of childhood cancer 
treatment, for example following irradiation of facial tissues, are 
also being developed and include the grafting of adipose tissue 
into affected areas [75]. Quality-of-life considerations in 
childhood cancer are also important and may differ, depending 
on the specific pathology. For example, evidence suggests that 
survivors of leukaemia have better quality of life than those with 
brain tumours [76]. 
Efforts to minimize the deleterious effects of childhood cancer 
treatment are also progressing [77]. Further research on the 
long-term health sequelae of surviving childhood cancer also 
appears warranted. There is evidence that irradiation, whole 
body or abdominal, can lead to an increase risk in developing 
type-2 diabetes mellitus [78] and, in females, complications in 
pregnancy have been described [79]. Increased risk of several 
long-term chronic health conditions, such as musculoskeletal 
disease, has been also observed in survivors of neuroblastoma 
[80]. Growth-hormone deficiency problems have also been 
described in childhood-cancer patients receiving cranial 
radiotherapy [81]. 
The scope for research and development on childhood cancer 
is considerable. This ranges from basic scientists continuing to 
develop pre-clinical cancer models, for example as 
demonstrated by work on hepatoblastoma [82], through to 
emergency department staff [83] as they may have 
opportunities to identify disease. The value of childhood cancer 
treatment being delivered by multidisciplinary teams appears 
important [84], especially when there is a high degree of 
distress within the family [85]. 
 
Closing remarks 
Many lines of contemporary research and development are 
active in the field of childhood cancer research. Given the 
extensive, although not conclusive, evidence base supporting a 
potential benefit of aspirin against cancer, studies on salicylate 
and childhood cancer risk appears worthwhile. Further 
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